Core Viewpoint - PVH's stock has dropped nearly 20% after lowering its full-year guidance despite exceeding Q1 expectations, raising questions about potential investment opportunities in the premium retailer's stock [1][3]. Group 1: Company Overview - PVH, formerly known as Phillips-Van Heusen Corporation, operates iconic fashion brands like Tommy Hilfiger and Calvin Klein, specializing in a wide range of apparel and accessories sold globally [2]. - The company has consistently surpassed earnings expectations, achieving a Q1 EPS of $2.30, exceeding the expected $2.24, although this represents a 6% decline from the previous year's $2.45 [5][6]. Group 2: Financial Performance - PVH reported Q1 sales of $1.98 billion, surpassing estimates of $1.93 billion and showing an increase from $1.95 billion in the prior period [6]. - The company has maintained an average earnings surprise of 13.47% and a sales surprise of 1.38% over the last four quarters [6]. Group 3: Guidance and Projections - PVH has lowered its EPS guidance for fiscal 2026 to between $10.75 and $11.00, down from a previous range of $12.40 to $12.75, and below the current Zacks Consensus of $12.59 [8][9]. - Despite the lowered guidance, Zacks projects a 13% increase in annual earnings for FY27 to $14.21, although EPS estimates may trend lower following the recent guidance [9]. Group 4: Valuation Metrics - PVH's stock is currently valued at 6.4X forward earnings, significantly lower than the Zacks Textile-Apparel Industry average of 13.3X, indicating a potential buying opportunity for long-term investors [11]. - The company's PEG ratio stands at 0.57, suggesting it is undervalued relative to its growth rate, and it trades at less than 1X forward sales [12]. Group 5: Investment Considerations - Following the Q1 report, PVH stock holds a Zacks Rank 3 (Hold), with potential for a rebound, but investors should monitor earnings estimate revisions closely [16]. - A decline in FY26 EPS estimates is anticipated, and a significant drop in FY27 estimates could indicate further downside risk [16][17].

Key Takeaways BJRI's shares surged 20.6% in a month, outperforming industry peers and nearing a 52-week high of $45.80. Comparable sales rose 1.7% in Q1, aided by strong traffic and operational upgrades driving guest satisfaction. Earnings estimates for 2025 rose 6.6% in 30 days, with EPS projected to climb 21.9% and revenues up 3.1%.BJ's Restaurants, Inc.’s (BJRI) shares have surged 20.6% in the past month, outpacing the industry and the S&P 500’s growth of 1.9% and 6.3%, respectively.On Wednesday, the s ...

Core Viewpoint - Chewy Inc's stock has experienced a downgrade from "buy" to "hold" by Jefferies, despite an increase in the price target from $41 to $43, primarily due to valuation concerns [1] Group 1: Stock Performance - Chewy's stock is down 2.8% in pre-market trading [1] - The stock has increased by 113% over the last 12 months and 41.2% year-to-date [1] - The stock reached a two-year high of $47.55 on June 3 [1] - The 10-day moving average has served as a reliable support level during recent pullbacks [1] Group 2: Analyst Sentiment - A majority of analysts remain positive, with 20 out of 28 covering firms maintaining a "buy" or better rating [2] - There is potential for sentiment to shift if momentum fades [2] - Short interest has decreased by 17.2% in the last two weeks, with 7.8% of the float sold short, which could support future gains [2] Group 3: Options Market - Options are currently pricing in relatively low volatility, with Chewy's Schaeffer's Volatility Index (SVI) at 65%, placing it in the 29th percentile of its annual range [2] - This suggests that options premiums are affordable [2]

Factors Influencing Newmont's Stock Movements in Recent Months Newmont (NYSE:NEM)'s stock has experienced quite a bit of volatility this year. It began the year on a weak note, primarily impacted by declining gold prices and concerns regarding costs and production delays. However, things started to improve as gold prices surged—thanks to global uncertainty and increased purchases by central banks. Thus far in 2025, NEM has made a solid recovery, regaining a significant portion of its previous losses. Althou ...

Core Viewpoint - The recommendation to buy the dip in Alphabet/Google (NASDAQ: GOOGL) remains unchanged despite the stock's underperformance since March 8 [1]. Group 1: Company Performance - Alphabet/Google has shown leadership in several sectors, indicating potential for recovery and growth [1]. Group 2: Analyst Background - The analyst has a background in IT and has been managing a family portfolio for seven years, which has led to a deep understanding of risk and reward in investments [1]. - The analyst aims to provide clear and accessible insights for investors of all experience levels, leveraging their IT background to navigate technology stocks [1].

Enterprise Products Partners (EPD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this provider of midstream energy services have returned +5.1%, compared to the Zacks S&P 500 composite's +5.2% change. During this period, the Zacks Oil and Gas - Production Pipeline - MLB industry, which Enterprise Products falls in, has gained 3.8%. The key questi ...

Core Viewpoint - CrowdStrike Holdings is considered overvalued at a price-to-earnings ratio of 122 times its adjusted trailing earnings, despite its impressive growth performance [1][6]. Group 1: Valuation and Growth - CrowdStrike's price-to-sales (P/S) ratio is 28.1, significantly higher than the S&P 500's 3.2, indicating a premium valuation [2]. - The company has achieved an average revenue growth rate of 40% over the past three years, compared to the S&P 500's 6.3% [2]. - In the most recent quarter, CrowdStrike's revenues grew by 20% to $1.1 billion, outperforming the S&P 500's growth rate [2]. Group 2: Profitability - Reported operating income for the last twelve months was -$252 million, resulting in a negative operating margin of -6.1% [3]. - On an adjusted basis, the operating margin was 20.3%, excluding stock-based compensation and one-time expenses [3]. - The company generated an operating cash flow of $1.4 billion, leading to a cash flow-to-sales ratio of 33.4%, which is significantly better than the S&P 500's 15.7% [3]. Group 3: Financial Stability - CrowdStrike has a debt of $785 million against a market capitalization of $122 billion, resulting in a low debt-to-equity ratio of 0.6% [4]. - Cash and cash equivalents amount to $4.6 billion, representing 53% of total assets, which is substantially higher than the S&P 500's 14.8% [4]. Group 4: Market Resilience - CrowdStrike's stock has shown greater volatility during market downturns, with a 58.3% decline during the 2022 Inflation Shock, compared to the S&P 500's 25.4% [5]. - During the 2020 Covid pandemic, the stock fell by 50.0%, again worse than the S&P 500's 33.9% decline [5]. - Although the stock recovered to pre-crisis levels, its higher volatility indicates weaker resilience during market crashes [5]. Group 5: Future Outlook - Current consensus estimates project average sales growth of 21% over the next couple of years, a slowdown from the previous three-year average of 40% [7]. - Given the high valuation and potential for a broader market downturn, it is suggested that now may not be the best time to invest in CrowdStrike stock [8].

SoundHound AI, Inc. (SOUN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this company have returned +8.5% over the past month versus the Zacks S&P 500 composite's +4.6% change. The Zacks Computers - IT Services industry, to which SoundHound AI belongs, has gained 2% over this period. Now the key question is: Where could the stock be headed in the near term?Although media re ...

Core Viewpoint - Pfizer's stock has declined approximately 25% from its 52-week high, primarily due to pipeline setbacks and management concerns regarding R&D spending and acquisitions [1][2][11] Valuation - Pfizer's current price-to-sales (P/S) ratio is 2.1, compared to 3.0 for the S&P 500, indicating it is slightly undervalued [8] - The price-to-free cash flow (P/FCF) ratio stands at 9.5 versus 20.5 for the S&P 500, and the price-to-earnings (P/E) ratio is 16.8 compared to 26.4 for the benchmark [8] Revenue Performance - Pfizer's revenues have seen a marginal decline over recent years, with an average shrinkage of 9.0% over the last three years, while the S&P 500 experienced a growth of 5.5% [8] - However, revenues grew by 11.7% from $60 billion to $64 billion in the last 12 months, outperforming the S&P 500's growth of 5.5% [8] Profitability - Pfizer's profit margins are around the median level for companies in the Trefis coverage universe, with an operating margin of 24.3% compared to 13.2% for the S&P 500 [8] Financial Stability - The company's balance sheet is considered weak, with a debt figure of $61 billion and a poor debt-to-equity ratio of 46.2% compared to 19.9% for the S&P 500 [13] - Cash and cash equivalents amount to $17 billion, yielding a cash-to-assets ratio of 8.3% versus 13.8% for the S&P 500 [13] Downturn Resilience - Pfizer's stock has historically underperformed the S&P 500 during market downturns, with a peak-to-trough decline of 57.3% from a high of $61.25 to $26.13 [14][15] - The stock has not yet recovered to its pre-crisis high, currently trading around $23 [14] Future Outlook - Despite current challenges, Pfizer has a robust pipeline, particularly in oncology, with potential blockbuster drugs that could enhance future revenues [12] - The acquisition of Seagen is beginning to positively impact sales and earnings, although it has not fully offset the revenue loss from COVID-19 products [10][12]

WASHINGTON, DC - APRIL 30: Shyam Sankar, CTO, Palantir Technologies speaks on stage during The Hill ... More & Valley Forum 2025 at The U.S. Capitol Visitor Center on April 30, 2025 in Washington, DC. (Photo by Tasos Katopodis/Getty Images for 137 Ventures/Founders Fund/Jacob Helberg )Getty Images for 137 Ventures/Founders Fund/Jacob HelbergPalantir Technologies (NASDAQ:PLTR) shares increased by approximately 7% during Friday’s trading session after The New York Times revealed that the U.S. government ...